share_log

艾美疫苗：自願性公告 - 艾美疫苗呼吸道合胞病毒(RSV)與帶狀疱疹兩款mRNA疫苗提交臨床試驗預申請

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FORTWO MRNA VACCINES OF RESPIRATORY SYNCYTIAL VIRUS (RSV)AND SHINGLES/HERPES ZOSTER OF AIM VACCINE SUBMITTED

Hong Kong Stock Exchange ·  Jun 4 21:38
Summary by Futu AI
艾美疫苗股份有限公司（「艾美疫苗」）於2024年6月向國家藥品監督管理局藥品審評中心提交了兩款mRNA疫苗的臨床試驗預申請，包括針對呼吸道合胞病毒(RSV)及帶狀疱疹的疫苗。RSV疫苗市場預計到2030年將達到約167億美元，而帶狀疱疹疫苗的市場規模則預計將達到中國約人民幣200億元，全球約239億美元。艾美疫苗作為國內最早開發mRNA疫苗產品的企業之一，已取得多項mRNA技術自主專利，並建立了完善的mRNA疫苗質量管理體系和商業化規模生產車間。公司表示，獲得臨床許可後將迅速實現mRNA疫苗產品的產業化，加快商業化進程。
艾美疫苗股份有限公司（「艾美疫苗」）於2024年6月向國家藥品監督管理局藥品審評中心提交了兩款mRNA疫苗的臨床試驗預申請，包括針對呼吸道合胞病毒(RSV)及帶狀疱疹的疫苗。RSV疫苗市場預計到2030年將達到約167億美元，而帶狀疱疹疫苗的市場規模則預計將達到中國約人民幣200億元，全球約239億美元。艾美疫苗作為國內最早開發mRNA疫苗產品的企業之一，已取得多項mRNA技術自主專利，並建立了完善的mRNA疫苗質量管理體系和商業化規模生產車間。公司表示，獲得臨床許可後將迅速實現mRNA疫苗產品的產業化，加快商業化進程。
In June 2024, Amy Vaccine Co., Ltd. submitted a preclinical trial application to the Drug Evaluation Center of the National Medical Products Administration for two mRNA vaccines, including vaccines for respiratory syncytial virus (RSV) and herpes zoster virus. The RSV vaccine market is expected to reach about $16.7 billion by 2030, while the market size for herpes zoster vaccine is expected to reach about RMB 20 billion in China and approximately $23.9 billion globally. As one of the earliest domestic enterprises to develop mRNA vaccine products, Amy Vaccine has obtained multiple mRNA technology patents and established a complete quality management system and commercial-scale production workshop for mRNA vaccines. The company stated that it will quickly realize the industrialization of mRNA vaccine products and accelerate the commercialization process after obtaining clinical approval.
In June 2024, Amy Vaccine Co., Ltd. submitted a preclinical trial application to the Drug Evaluation Center of the National Medical Products Administration for two mRNA vaccines, including vaccines for respiratory syncytial virus (RSV) and herpes zoster virus. The RSV vaccine market is expected to reach about $16.7 billion by 2030, while the market size for herpes zoster vaccine is expected to reach about RMB 20 billion in China and approximately $23.9 billion globally. As one of the earliest domestic enterprises to develop mRNA vaccine products, Amy Vaccine has obtained multiple mRNA technology patents and established a complete quality management system and commercial-scale production workshop for mRNA vaccines. The company stated that it will quickly realize the industrialization of mRNA vaccine products and accelerate the commercialization process after obtaining clinical approval.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.